Aurinia Pharmaceuticals Inc (AUPH)vsVertex Pharmaceuticals Inc (VRTX)
AUPH
Aurinia Pharmaceuticals Inc
$16.21
0.00%
HEALTHCARE · Cap: $2.17B
VRTX
Vertex Pharmaceuticals Inc
$542.62
-0.81%
HEALTHCARE · Cap: $141.65B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 3812% more annual revenue ($12.59B vs $321.74M). AUPH leads profitability with a 97.7% profit margin vs 35.0%. AUPH trades at a lower P/E of 7.1x. VRTX earns a higher WallStSmart Score of 62/100 (C+).
AUPH
Buy59
out of 100
Grade: C
VRTX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AUPH.
Margin of Safety
+42.4%
Fair Value
$949.93
Current Price
$542.62
$407.31 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 98 of every $100 in revenue as profit
Strong operational efficiency at 51.6%
Conservative balance sheet, low leverage
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 97.7% and operating margin at 51.6%. Revenue growth of 13.9% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : AUPH
The primary concerns for AUPH are EPS Growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
AUPH carries more volatility with a beta of 1.34 — expect wider price swings.
AUPH is growing revenue faster at 13.9% — sustainability is the question.
VRTX generates stronger free cash flow (546M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (62/100 vs 59/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?